A1C and fasting glucose: the two metabolic baselines
Two lab values. Two different time windows. Together they give a clinician the clearest picture of where your glucose metabolism stands.
TL;DR
- A1C reflects average blood glucose over approximately 3 months — it’s a long-window average, not a snapshot.
- Fasting glucose is a point-in-time measurement taken after at least 8 hours without caloric intake.
- ADA diagnostic thresholds: A1C below 5.7% is normal; 5.7–6.4% is prediabetes; 6.5% or above indicates diabetes.
What it is
A1C (hemoglobin A1c) measures the percentage of hemoglobin molecules in red blood cells that have glucose attached to them. Because red blood cells have a lifespan of roughly 90 days, A1C integrates glucose exposure over that full period. A single dietary indiscretion doesn’t meaningfully move A1C — but a sustained pattern of elevated glucose will. Fasting glucose, by contrast, measures the concentration of glucose in the blood at a specific moment after an overnight fast. It’s more reactive to recent dietary choices and short-term metabolic state. Together, the two markers provide complementary information: A1C tells you about the trend; fasting glucose tells you about the present. The American Diabetes Association Standards of Care publish the definitive diagnostic thresholds used in clinical practice (ADA Standards of Care, 2025).
How it works
The ADA diagnostic thresholds (2025):
| Category | A1C | Fasting Glucose |
|---|---|---|
| Normal | < 5.7% | < 100 mg/dL |
| Prediabetes | 5.7% – 6.4% | 100–125 mg/dL |
| Diabetes | ≥ 6.5% | ≥ 126 mg/dL |
A single elevated result in either category does not constitute a diagnosis — ADA guidelines recommend confirmation with a repeat test on a separate day, or concordant results from a second test.
Who asks about it
People preparing for a RESHAPE (GLP-1) consultation often ask about these two tests because they appear on the intake lab panel. Others come from a general metabolic health interest — they’ve received their annual physical results and want to understand where 5.9% actually sits on the spectrum.
What the research says
The ADA Standards of Care 2025 document identifies the prediabetes range as an area of significant clinical intervention opportunity — structured lifestyle programs in this range have been shown to reduce the rate of progression to type 2 diabetes by roughly 58% in large randomized trials (Knowler et al., NEJM, 2002 — the Diabetes Prevention Program). That same population is frequently evaluated for GLP-1 protocols, where metabolic baseline data directly informs prescribing decisions and follow-up cadence.
What to know before considering it
A1C can be artificially low in people with certain hemoglobin variants, recent blood loss, or hemolytic anemia. In those cases, fasting glucose or a 2-hour oral glucose tolerance test may be the preferred diagnostic tool. A clinician evaluating your metabolic status will consider your full picture — not just one number.
The Halftime POV
Knowing your A1C and fasting glucose before starting any metabolic protocol is basic due diligence — and it’s data that pays dividends beyond the protocol itself. These two numbers are among the most predictive early indicators of cardiometabolic risk, and most people have never seen them plotted against where they actually want to be.
Related reading:
FAQ
Q: What is the difference between A1C and fasting glucose? A: Fasting glucose measures blood sugar at a single point in time — typically after an 8-hour fast. A1C (glycated hemoglobin) reflects average blood glucose over approximately 2–3 months by measuring the percentage of hemoglobin that has been glycated. They provide complementary pictures: fasting glucose is immediate; A1C is the running average.
Q: What are the ADA diagnostic thresholds for A1C? A: Per American Diabetes Association guidelines: A1C below 5.7% is normal; 5.7–6.4% is prediabetes; 6.5% or above on two separate tests indicates diabetes. Fasting glucose below 100 mg/dL is normal; 100–125 mg/dL is prediabetes (impaired fasting glucose); 126 mg/dL or above on two occasions indicates diabetes.
Q: Why are A1C and fasting glucose relevant before a GLP-1 protocol? A: GLP-1 receptor agonists have documented effects on blood glucose — they are approved for type 2 diabetes management. Before initiating a GLP-1 protocol, establishing metabolic baseline (A1C and fasting glucose) is standard clinical practice. These markers also help monitor response and guide dose adjustments over time.
Disclaimer
This article is educational and is not medical advice. Compounded GLP-1 medications are prepared by state-licensed 503A compounding pharmacies from FDA-approved active pharmaceutical ingredients and are not themselves FDA-approved. GLP-1 therapies are available only with a valid prescription following a licensed clinician evaluation. Clinical outcomes depend on individual factors including baseline health, adherence, diet, and physical activity. Individual results vary. Side effects are common and may include nausea, injection-site reactions, and gastrointestinal symptoms. Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.
Sources
- American Diabetes Association Standards of Care in Diabetes — 2025 (Supplement 1)
- Knowler WC et al., “Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin” — NEJM, 2002
- A1C test overview — NIH MedlinePlus
